Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi-synthelabo ireland ltd - nalidixic acid - oral suspension - 300 mg/5ml

Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited - nalidixic acid - tablets - 500 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

pco manufacturing - nalidixic acid - tablets - 500 milligram

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-synthelabo (nz) limited - nalidixic acid 500mg - tablet - 500 mg - active: nalidixic acid 500mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sanofi - nalidixic acid - oral tablet - 500mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sanofi-synthelabo ltd - nalidixic acid - oral suspension - 60mg/1ml

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

sanofi-synthlabo - nalidixic acid - tablet - 500 mg

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - melphalan 50mg - solution for injection - 50 mg - active: melphalan 50mg excipient: hydrochloric acid povidone ethanol propylene glycol sodium citrate dihydrate

Australia - English - Department of Health (Therapeutic Goods Administration)

amdipharm mercury australia pty ltd - zonisamide, quantity: 100 mg - capsule, hard - excipient ingredients: allura red ac; sodium lauryl sulfate; hydrogenated vegetable oil; titanium dioxide; microcrystalline cellulose; sunset yellow fcf; gelatin; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - zonegran is indicated as: - monotherapy in the treatment of partial seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy who are intolerant to other agents or where other agents are contraindicated. - adjunctive therapy in the treatment of adult patients with partial seizures, with or without secondary generalisation.

Australia - English - Department of Health (Therapeutic Goods Administration)

amdipharm mercury australia pty ltd - zonisamide, quantity: 50 mg - capsule, hard - excipient ingredients: titanium dioxide; microcrystalline cellulose; sodium lauryl sulfate; gelatin; iron oxide black; hydrogenated vegetable oil; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; potassium hydroxide - zonegran is indicated as: - monotherapy in the treatment of partial seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy who are intolerant to other agents or where other agents are contraindicated. - adjunctive therapy in the treatment of adult patients with partial seizures, with or without secondary generalisation.